Korsana Posts $46.4M Q3 Loss, $456M Cash Funds Operations Into 2029
KRSA has more than doubled off its 52-week low of $7.186.
Summary
Korsana reported a $46.4M third-quarter net loss and $456.2M in cash, which it says funds operations into 2029 — past the mid-2027 Phase 1 readout for its Alzheimer's antibody KRSA-028.
Key Events · Earnings and Guidance · KRSA
-
Q3 Net Loss Widens to $46.4M
Net loss was $46.4M for the third quarter of 2026 versus $21.7M a year earlier, including $15.2M of non-cash stock-based compensation.
-
Cash Runway Extends Into 2029
Cash and cash equivalents stood at approximately $456.2M as of September 30, 2026, following the Cyclerion merger and concurrent $380M private placement; management expects this to fund operations into 2029.
-
KRSA-028 Data Timelines Set
Phase 1 healthy volunteer data for KRSA-028 is expected mid-2027, with interim proof-of-concept data in Alzheimer's patients anticipated by year-end 2027 or the first quarter of 2028.
-
CTAD Poster on November 18
Preclinical characterization data for KRSA-028 (poster P338) will be presented at the CTAD 2026 conference on Wednesday, November 18, 2026.
Analysis · KRSA · Life Sciences
The balance sheet, not the income statement, is the quarter's headline: $456.2M of cash after the September merger with Cyclerion and the concurrent $380M private placement gives Korsana a runway into 2029. That covers the KRSA-028 Phase 1 readout expected mid-2027 and the interim Alzheimer's proof-of-concept data targeted for late 2027 or early 2028. The $46.4M net loss is a step up from $21.7M a year ago, but $15.2M of it is non-cash stock compensation tied to the merger and leadership build-out, so cash burn is smaller than the headline. With the financing already done, the next hard checkpoint is the CTAD preclinical poster on November 18, 2026, followed by the 2027 clinical data.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KRSA was trading at $30.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $7.19 to $59.36. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.